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Neural stem cells restore myelin in a
demyelinating model of Pelizaeus-Merzbacher
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Pelizaeus-Merzbacher disease is a fatal X-linked leukodystrophy caused by mutations in the PLP1 gene, which is expressed in the
CNS by oligodendrocytes. Disease onset, symptoms and mortality span a broad spectrum depending on the nature of the mutation
and thus the degree of CNS hypomyelination. In the absence of an effective treatment, direct cell transplantation into the CNS to re-
store myelin has been tested in animal models of severe forms of the disease with failure of developmental myelination, and more re-
cently, in severely affected patients with early disease onset due to point mutations in the PLP1 gene, and absence of myelin by MRI.
In patients with a PLP1 duplication mutation, the most common cause of Pelizaeus-Merzbacher disease, the pathology is poorly
defined because of a paucity of autopsy material. To address this, we examined two elderly patients with duplication of PLP1 in
whom the overall syndrome, including end-stage pathology, indicated a complex disease involving dysmyelination, demyelination and
axonal degeneration. Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of transplanted neural stem
cells to restore myelin in the context of PLP overexpression. Although developmental myelination and axonal coverage by endogenous
oligodendrocytes was extensive, as assessed using electron microscopy (n = 3 at each of four end points) and immunostaining (n = 3 at
each of four end points), wild-type neural precursors, transplanted into the brains of the newborn mutants, were able to effectively
compete and replace the defective myelin (n = 2 at each of four end points). These data demonstrate the potential of neural stem cell
therapies to restore normal myelination and protect axons in patients with PLP1 gene duplication mutation and further, provide proof
of principle for the benefits of stem cell transplantation for other fatal leukodystrophies with ‘normal’ developmental myelination.
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Introduction
The leukodystrophies comprise a group of genetic disor-
ders that primarily affect the white matter of the CNS (van
der Knaap and Bugiani, 2017). Pelizaeus-Merzbacher dis-
ease (PMD), the prototypic hypomyelinating leukodystro-
phy, is caused by mutations in the highly conserved, X-
linked PLP1 gene (Gencic et al., 1989; Boespflug-Tanguy
et al., 1994; Garbern et al., 1999), which encodes proteoli-
pid protein (PLP) and its isoform DM20 (Nave et al.,
1987). PLP and DM20 are located in compact myelin
where they contribute to the normal spacing of the intra-
period line (Boison and Stoffel, 1994; Klugmann et al.,
1997; Yool et al., 2002).
Mutations in the PLP1 gene are associated with a broad
spectrum of neurological disorders ranging from severe con-
natal forms of PMD through intermediate severity, classical
forms and PLP1 null spectrum disorder, to the milder allelic
disorder, spastic paraplegia 2 (SPG2) (Garbern and Hobson,
2002; Garbern et al., 2002; Garbern, 2007; Oso´rio and
Goldman, 2018). The symptoms of PMD have an early
onset and typically include motor and cognitive impairment,
nystagmus, choreoathetosis, seizures and ataxia. The under-
lying pathogenesis of PLP1 syndromes is distinct for the dif-
ferent genetic abnormalities, which include point mutations,
duplication or triplication of the PLP1 locus and deletion
mutation (Woodward, 2008; Torii et al., 2014; Inoue, 2017;
Nevin et al., 2017; Oso´rio and Goldman, 2018), partly
accounting for the broad clinical spectrum. Modifier genes
likely also contribute (Al-Saktawi et al., 2003). Duplications
of the PLP1 locus represent the most common cause of
PMD (Sistermans et al., 1998; Mimault et al., 1999); how-
ever, variation in the size and break points of the duplicated
region on the X chromosome and in the site of recombin-
ation likely contribute to the range of severity, even within
this genetic subtype (Inoue et al., 1999; Hodes et al., 2000).
To date, no effective treatment is available for PMD, al-
though deferiprone, an iron chelator, reduced oligodendro-
cyte apoptosis and facilitated myelin formation in the jimpy
mouse model of connatal PMD (Nobuta et al., 2019), and
ketogenic diet (Stumpf et al., 2019), cholesterol supplemen-
tation (Saher et al., 2012) and transcriptional suppression by
artificial microRNA (Li et al., 2019) have proven beneficial
in Plp1-overexpressing animal models. Stem cell therapy for
PMD has undergone a clinical safety trial in four patients
with connatal forms due to point mutations in the PLP1
gene, in whom myelin is absent by MRI (Gupta et al., 2012,
2019). The question therefore arises whether stem cell ther-
apy might be safe and effective in patients with the most
common mutation (PLP1 duplication), who have, in general,
milder pathology and longer life expectancy (Cremers et al.,
1987; Sistermans et al., 1998) and in whom the basis for the
hypomyelination is likely attributable, at least in part, to loss
of previously formed myelin (demyelination) (Inoue et al.,
1996; Anderson et al., 1998, 1999; Edgar et al., 2010) and
inflammation (Ip et al., 2006; Edgar et al., 2010; Marteyn
and Baron-Van, 2016) as suggested from observations in
Plp1/PLP1-overexpressing animal models. This also raises
the question whether the exogenous, wild-type oligodendro-
cytes are able to physically replace myelin made by mutant
oligodendrocytes.
Here, we examined two elderly patients with duplication
of PLP1 in whom the overall syndrome, including end-stage
pathology, indicated a complex disease involving dysmyeli-
nation, demyelination and axonal degeneration. We then
systematically characterized myelin development, degener-
ation and neuroinflammation in a corresponding Plp1-trans-
genic mouse model (Plp1-tg mouse, line 72; Readhead et al.,
1994) and tested whether cell transplantation directly into
the brain could restore normal myelin. We transplanted
neural precursors (NPCs) based on earlier observations that
murine NPCs form myelin when transplanted into the Plp1
mutant myelin deficient (md) rat (Hammang et al., 1997)
and the Mbp mutant shiverer mouse (Edgar et al., 2004); a
result that was subsequently replicated in shiverer mice using
human-derived NPCs (Buchet et al., 2011; Uchida et al.,
2012).
We found that transplanted wild-type NPCs were able to
differentiate and produce large amounts of compact myelin
in Plp1-tg mice, against a background of normal-appearing
myelination by endogenous mutant oligodendrocytes. This
raises the possibility that similar transplantation-based ther-
apy may work in PMD and other leukodystrophies, in
which a normal-appearing developmental myelination is fol-
lowed by progressive demyelination and inflammation.
Material and methods
Human tissue and histology
Duplication of the PLP1 locus was confirmed by quantita-
tive reverse transcription-PCR as described previously
(Inoue et al., 1999; Hobson et al., 2000). PMD brains
were removed at autopsy by J.G. (Sima et al., 2009) and
the cerebral and cerebellar hemispheres separated. One
hemisphere from each region was fixed in 10% buffered
formalin for histological analysis and the other was sliced
in 1-cm thick sections and immediately snap frozen on
dry ice and stored at –70C. Several 1-cm axial sections of
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the spinal cord of Patient 1 were removed from different
levels and frozen; the remainder were fixed in 10% buf-
fered formalin. For the analysis described in this report,
samples of the cerebral cortex, optic nerve, cerebellum and
medulla from both brothers, and the cervical and lumbar
cord from Patient 1 were used. Tissue was paraffin wax-
embedded or cryoprotected in 20% sucrose and snap fro-
zen. Selected regions were further fixed in glutaraldehyde,
osmicated and processed for resin embedding. Paraffin sec-
tions were stained with haematoxylin and eosin or
Holmes’ silver impregnation or immunostained by the PAP
technique with rabbit anti-PLP1/DM20 (antibody to C-ter-
minal, recognizing both isoforms), rabbit anti-PLP1 iso-
form (antibody to the PLP1-specific region), rat
anti-myelin basic protein (MBP; Serotec MCA4095) and
rabbit-glial fibrillary acidic protein (GFAP; Dako Z0334).
Phosphorylated and non-phosphorylated epitopes on the
neurofilament-H protein were immunostained with SMI-
31 and SMI-32 (Covance mouse SMI31-R and SMI32-R)
antibodies, respectively. Indirect immunofluorescence was
also used to stain paraffin and cryosections. Control
human material was obtained at autopsy. Respective CNS
regions were fixed in formalin and embedded in paraffin.
Paraffin sections were stained with haematoxylin and
eosin and immunostained using the DAB technique for
anti-myelin basic protein (MBP; Cell Marque) or with im-
munofluorescence with antibodies against phosphorylated
neurofilament-H (Covance, SMI 31R) and MBP,
respectively.
Myelin isolation and western
blotting
Frozen tissue obtained at autopsy, as described above, or
fresh human control brain biopsy material that had been im-
mediately frozen after isolation, was stored at –70C. For
myelin purification, tissue samples from the frontal lobes
containing either a mixture of grey and white matter or
white matter only were isolated while the tissue was still fro-
zen, powdered with mortar and pestle in liquid nitrogen and
200 mg of material processed (Norton and Poduslo, 1973).
In brief, tissue was homogenized using a Polytron blender in
0.85 M sucrose, 10 mM HEPES pH 7.4, 2 mM DTT and
1 mM TLCK. Sucrose (0.25 M) was gently layered on top
of the homogenate, which was then centrifuged at 70000g
for 90 min at 4C. The myelin interface was removed and
hypotonically lysed in chilled dH2O and pelleted at 23000g
for 30 min at 4 C. Following an additional two rounds of
hypotonic lysis, the myelin pellet was resuspended in 10
mM HEPES pH 7.4 containing 1 mM PMSF, 1 mM benza-
midine, 10 lg/ml aprotinin and 10 lg/ml leupeptin. Myelin
fractions were stored at –70C. The protein concentration
was determined using a Bio-Rad method using bovine serum
albumin as a standard (Bio-Rad). Western blotting for PLP1/
DM20, myelin-associated glycoprotein (MAG), MBP, and
20,30-cyclic-nucleotide 30-phosphodiesterase (CNP) was
performed using the enhanced chemiluminescence (ECL)
method. The sensitivity was confirmed by loading different
amounts of selected samples.
For control purposes, we used brain with no neurological
disease, from a 70-year-old female who died of congestive
heart failure and tissue (stored at –70C) from a cerebral bi-
opsy of a 2-year-old female undergoing surgery for removal
of an epileptic focus that pathologically showed cortical glio-
sis. Normal-appearing white matter adjacent to the epileptic
focus was immediately snap frozen for subsequent myelin
preparation, as described above.
Pelizaeus-Merzbacher disease
mouse model
The Plp1-overexpressing line #72 (Readhead et al., 1994) on
a C57BL/6N background, Thy-1-CFP (Feng et al., 2000), b-
actin-GFP (Ikawa et al., 1995) and PLP1-LacZ (Wight et al.,
1993) mice were used. The Plp1-tg #72 line harbours a cas-
sette with three extra copies of the Plp1 gene (Readhead
et al., 1994). Hemizygous mice were bred to generate homo-
zygous transgene positive (Plp1-tg) and wild-type offspring.
PCR was used to confirm the presence of the transgene and
quantitative real-time PCR (outsourced to Embark Scientific)
was used to ascertain gene copy number, to distinguish
homozygous from hemizygous mice. For axon morphology,
Thy-1-CFP1 mice (B6.Cg-Tg Thy1-CFP 23Jrs/J) were crossed
with Plp1-tg mice for at least six generations then homozy-
gous Plp1-tg: hemizygous Thy-1-CFP offspring were used.
Transplant recipients were male and female postnatal Day 1
(P1) or male P100 offspring of homozygous Plp1-tg parents.
Mice were bred in designated animal facilities, Biological
Services, University of Glasgow (UoG). All experiments were
conducted according to guidelines in the Animal’s Scientific
Procedures Act 1986 under a project license (PPL 01/0507)
from the UK Home Office, and approved by the local Ethics
and Welfare review panel of the Faculty of Veterinary
Medicine, UoG. Further details on housing are available in
the online Supplementary material.
Collection and preparation of
animal tissue
Mice were rapidly perfusion fixed at ages P40, P60, P90 or
P120 with 0.9% saline followed by 4% paraformaldehyde
(PFA) for immunohistochemistry or 4% PFA/5% glutaralde-
hyde in 0.08 M cacodylate buffer (pH 7.2), 0.05% calcium
chloride (‘strong’ fixative) for electron microscopy, immersed
for41 h in fixative, then dissected.
For immunohistochemistry, whole brain was cryoprotected
in 20% sucrose/PBS, immersed in O.C.T. compound (Sakura
Finetec) then snap frozen in liquid nitrogen-chilled isopentane
and sectioned on an OTF cryostat (Bright Instruments) at
10 mm. For electron microscopy, brains were cut into 10
mm3 pieces, osmicated in 1% osmium tetroxide, dehydrated
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through a series of increasing concentrations of ethanol,
cleared in propylene oxide, and embedded in AralditeV
R
.
For light microscopy of resin-embedded tissue, sec-
tions were cut at 1 lm and stained with methylene blue
(VWR)/azur II (VWR), then mounted on glass slides in
DPX (VWR). For electron microscopy, 60 nm sections
were stained with uranyl acetate (AGAR Scientific,
R1260) and lead citrate (VWR, 290384R). Imaging was
performed in the region where the fimbria merges with
the corpus callosum, rostrodorsal to the hippocampus,
using a JEOL 100CX electron microscope. After neuro-
sphere transplantation, GFP or LacZ-positive tissue
was post-fixed by immersion in ‘strong’ fixative for 1
week.
Antibodies and protocols for staining mouse tissue are
provided in the Supplementary material.
Neurospheres
Neurospheres were generated as described previously (Edgar
et al., 2004) from newborn homozygous PLP-LacZ or hemi-
zygous b-actin-GFP mice. On the day of transplantation,
LacZ and GFP expressing neurospheres were mixed
together in 50:50 ratio, triturated lightly through a flame-
polished glass pipette and resuspended following centrifuga-
tion in 20–30 ml ice-cold L15, corresponding to at least
50000 cells/ml.
Transplantation into the adult
corpus callosum
Anaesthesia was induced in P100 mice with 5% isoflurane
and maintained with 2% isoflurane, both in 30% O2/70%
NO2. Deeply anaesthetized animals were fixed in a rodent
stereotactic frame. Right-sided craniectomies were per-
formed, and a glass capillary connected to a microinfusion
pump (CellTram Oil manual piston pump, Eppendorf) was
placed according to stereotactic coordinates (Paxinos and
Franklin, 2001) –0.58 mm or 1.34 mm caudal to bregma,
and 0.5 mm lateral to the midline suture and 1.5 mm ven-
trally to the brain surface. A 1 ll neurosphere suspension
was injected at 0.1 ll/min. Pre- and post-surgical analgesia
was provided.
Transplantation in neonates
Newborn pups (P1) were anaesthetized with 5% isoflurane
in O2 and transferred to a 37
C heating pad. The head was
fixed gently between the operator’s fingers and four injec-
tions were made using a tapered 30-G needle attached to a
5 ll Hamilton syringe (Hamilton 65RN) to a depth of
1.5 mm, immediately right and left of bregma point 0, and
immediately right and left of lambda. A 0.5 ll neurosphere
suspension was administered slowly at each site.
Administration of
bromodeoxyuridine
A single intraperitoneal injection of 50 mg/g body weight 5-
bromo-2-deoxyuridine (BrdU; Sigma-Aldrich, Cat. B5002) in
physiological saline was administered 1 h prior to perfusion
fixation in 4% PFA.
Cell quantification
Cell densities were measured on micrographs on which a
rectangular area of interest of known area was placed. All
cells with a nucleus within or whose nucleus crossed south
and west borders were counted.
Quantification of cells labelled using immunofluorescence
was performed in the corpus callosum on 10-mm thick trans-
verse cryosections. Six or more sections, at 100-mm intervals,
were stained with each antibody. One image per section was
taken at 40 magnification; six or more images per anti-
body were quantified as described previously (Edgar et al.,
2010).
Quantification of cells in resin sections was performed in
the corpus callosum on 375–500-nm thick sections stained
with methylene blue/azur II, imaged using a 100 oil ob-
jective. Cells were identified as activated microglia/macro-
phages on the basis of having a dense, dark cytoplasm,
which was obvious at the level of the light microscope, and
a characteristic ‘angular’ shape.
Electron microscopy to identify cell types was done on a
JEOL 100CX microscope with digital camera. Images were
captured at 600, 1000 and 1500 magnification to
allow characteristic features (rough endoplasmic reticulum,
Golgi apparatus, mitochondria, microtubules, lysosomes,
glial filaments) to be observed.
Morphometry from electron
micrographs
Eight electron micrographs per animal were captured at ran-
dom from the mid corpus callosum at 8000 using a film
camera (JEOL 100CX). Negatives were scanned (Epson
Perfection 3200 Photo) and images evaluated in ImagePro
6.0. Total axon densities were counted within, and on north
and west borders of 45-mm2 areas of interest. For percentage
myelinated axons, axons were quantified if they occurred on
four overlaid bisecting lines and ascribed as myelinated or
non-myelinated.
Oligodendrocyte precursor cell
culture and assessment of process
length
For each adult oligodendrocyte precursor cell (aOPC) co-
culture, two adult wild-type GFP-expressing and two adult
Plp1-tg corpus callosa were used. Plp1-tg and GFP-express-
ing wild-type OPCs were mixed in equal numbers and plated
at a concentration of 105 cells/13-mm diameter glass
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coverslip coated with poly-L-lysine. OPCs were obtained
from whole brains of P5 mice, as above, but cells were
plated at 3–4  104 cells/coverslip. Adult and neonatal
OPCs were obtained using identical dissociation and centri-
fugation protocols. See Supplementary material for further
details.
To evaluate total process length per cell, six semi-random-
ly chosen fields per coverslip were photographed using phase
and fluorescence microscopy (Olympus IX-70, 20 object-
ive). Semiautomatic tracing of OPC processes was carried
out in ImageJ using the NeuronJ plug-in on phase micros-
copy images.
Statistical analysis and graphical
presentation of the data
An unpaired Student’s t-test was used to compare cell den-
sities, axonal densities and percentage myelinated axons.
Statistical analysis and the graphical presentation of data
were performed using GraphPad Prism 5V
R
. For OPC
process length comparison, a two-tailed Mann-Whitney test
was used as the data were not normally distributed. This
analysis was done using GraphPad Prism 8V
R
. P-values are
indicated as *P5 0.05, **P50.01, ***P5 0.001 and
****P5 0.0001.
Data availability
The data that support the findings of this study are available
from the corresponding author, upon reasonable request.
Results
Clinical and MRI assessment is
compatible with CNS
hypomyelination
The patients described here are members of a family previ-
ously described (Watanabe et al., 1973; Wilkus and Farrell,
1976), and are in the sibship of three brothers, two of
whom were affected (Generation VI). The duplication is
509297 bp in size (Woodward et al., 2005; Patient P116).
Quantitative RT-PCR analysis demonstrated an 1.25-fold
higher level of PLP1 gene expression than in a patient with
multiple sclerosis (Supplementary Table 1).
Patient 1
After an uncomplicated full-term pregnancy and delivery,
Patient 1 was noted to have nystagmus within the first 2
weeks after birth. By 6 months of age it was apparent his
gross motor development was delayed. He was hypotonic
during infancy and required head support. He was delayed
for rolling over and was not able to sit without support until
30 months old. He was never able to walk. Spasticity was
noted beginning at about age 15 and progressed,
necessitating tendon releases in the hip adductors in the
fourth and fifth decades. The patient could perform simple
tasks such as finger feeding, but movements were ataxic. By
30 years of age he required full assistance for feeding.
Speech developed at a normal age and until about age 17 he
was able to verbally communicate effectively. After that age,
speech became progressively more dysarthric and he was un-
able to speak after about age 30. Cognition was impaired
and the patient was educated in special education settings
until transferred to an institution for developmentally
impaired children when he was 12 years old. He remained
incontinent throughout his life. He enjoyed watching sports
and recognized names of the local sporting teams. The pa-
tient was examined at age 51 (by J.G.). At that time the pa-
tient was alert and could recognize family members and
caretakers. He was able to perform simple commands, but
speech was absent. Most communication was through hand
signals and facial expression. He was able to communicate
using an electronic touch-sensitive communication board.
Head titubation and compensatory nystagmus were present
when his head was not supported while sitting, but both
ceased when his head was supported. Upper extremity
strength was 3/5 on the MRC scale, with spasticity and con-
tractures at the biceps and wrist flexors. The patient required
a thoracic brace and headrest to maintain upright posture
while sitting in his wheelchair. The legs were very atrophic,
but no fasciculations were noted. There was no voluntary
leg movement. Reflexes were abnormally brisk and Babinski
signs and triple flexion were elicited on plantar stimulation.
Arm movements were slow and ataxic. The patient required
a feeding tube for the last year of life and died of aspiration
pneumonia at age 54.
Patient 2
Patient 2 had a similar clinical course except that his mother
did not note nystagmus at any age. Clinical examination of
Patient 2 at age 45 was essentially the same as that of his
brother. He also required a feeding tube for the last year of
life and he expired at age 47 of aspiration pneumonia. An
MRI scan at age 41 (Fig. 1) showed diffuse white matter sig-
nal hyperintensity on T2-weighted images with enlarged ven-
tricles and reduced white matter volume (Fig. 1A and B).
The T1 signal was also diffusely reduced (Fig. 1C), and the
corpus callosum markedly thinned (Fig. 1D).
To determine how PLP1 duplication affected levels of
PLP/DM20 and other major myelin proteins, we used
western blotting. There was no evidence of protein degrad-
ation in the patients’ samples, assessed against fresh biopsy
material. Myelin preparations from mixed grey and white
matter or almost entirely white matter were assessed. The
levels of the PLP1 and DM20 isoforms were approximate-
ly twice the amount observed in the controls. MBP levels
were comparable between the PMD and controls whereas
the levels of CNP and MAG, two proteins of non-compact
myelin, were markedly reduced in the PMD samples
(Fig. 2).
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In summary, the clinical and MRI evaluations were con-
sistent with classical PMD, and demonstrated a slowly pro-
gressive deterioration of neurological function. Biochemical
analysis confirmed increased levels of PLP/DM20 in PMD
brain, as anticipated from the molecular diagnosis.
Pathology involves dysmyelination,
demyelination and axon
degeneration
Examination of the brains at autopsy revealed generalized
reduction of cerebral white matter with relative sparing of
U-fibres. The cortical ribbon was of appropriate thickness.
Cerebellar white matter was globally reduced. There was
marked atrophy of the cerebral peduncles and corticospinal
tracts. Pigmentation of the substantia nigra was reduced.
Neuronal loss and gliosis were noted in several regions
including substantia nigra, amygdala, anterior striatum and
in entorhinal, anterior cingulate, insular and parietal cortices
and the thalamus, in particular the pulvinar and dorsal med-
ial nucleus. The spinal cord of Patient 1 was severely atro-
phied being 6 mm in diameter at the cervical and lumbar
levels (Fig. 3), compared to an average of 7.7 and 8.0 mm,
respectively, reported previously (Elliott, 1945). A more
detailed analysis of the neuronal changes is presented else-
where (Sima et al., 2009).
Based on the above, we selected specific regions for a
more detailed analysis of myelin and axonal changes.
Histological findings in the material common to both broth-
ers were similar. Paraffin sections of spinal cord generally
stained strongly for both PLP1/DM20 and MBP although
areas of pallor were present in the centre of the posterior
Figure 2 Western blot of myelin extracts from PMD and
control human brain show altered levels of myelin proteins.
Ctl1 is stored tissue from 70-year-old brain and Ctl2 is fresh biopsy
material from 2-year-old brain white matter. Myelin was extracted
from tissue that was composed of a mixture of grey and white mat-
ter or tissue that was composed almost entirely of white matter.
For PLP and MBP analysis, 0.25 lg of the PMD myelin was loaded; in
the control patients 0.25 lg (equal symbol) and 0.5 lg (2) of the
samples were loaded onto the gel. For CNP and MAG analysis, 1.5
lg of the PMD myelin and 1.5 lg (equal symbol) and 3 lg (2) of
the control samples were loaded onto the gel. Graphs provide
semiquantitative data reflecting band intensities. The y-axis values
are the same in the two graphs. Blots were cropped for display pur-
poses. Full-length blots are available in the Supplementary material.
Figure 1 MRI scan of Patient 2 at age 41 illustrates
reduced white matter. (A and B) T2-weighted axial sections
showing the diffusely increased signal in the cerebral white matter;
however, there is a thin, normal signal in the corpus callosum and
the internal capsule. (C and D) T1-weighted images showing the
reduced amount of white matter: note the thinness of the corpus
callosum and of the fingers of white matter extending into cortical
gyri in C. Thinning of the corpus callosum and of the cervical spinal
cord can be observed in D. Reference T1 and T2 MRI images of
healthy individuals can be found in publicly available MRI brain
atlases, such as the Whole Brain Atlas by the Harvard Medical
School http://www.med.harvard.edu/AANLIB/cases/caseNA/pb9.htm
or the IMAIOS webservice https://doi.org/10.3701.9/e-anatomy/163.
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Figure 3 Evidence for dysmyelination, demyelination and axon degeneration in PMD. (A and B) Cervical and lumbar cord (Patient
1) stained for MBP. While the majority of white matter is stained strongly, symmetrical areas of pallor are present in the central posterior col-
umns (short arrows) and the periphery of the lateral columns (arrows) in A and in the posterior columns (short arrows) in B. Scale bars =
2 mm. (C and D) Sections from control for comparison. Scale bars = 2 mm. (E and F) Regions of the fasciculus gracilis (F. gracilis) and peripheral
fasciculus cuneatus (F. cuneatus) double immunostained for MBP (green) and phosphorylated heavy chain neurofilament (NF, red). (G and H)
Sections from control for comparison. Scale bars = 50 mm. There are a reduced number of fibres in the F. gracilis and many axons have no myelin
sheath. In the F. cuneatus the majority of axons have a myelin sheath. (I) Resin section from periphery of lateral columns. There is a marked re-
duction in myelinated nerve fibres and replacement by astrocytic processes. A swollen axon (large arrow) and axons with thin myelin sheaths
(small arrow) are present. Scale bar = 10 lm. (J) Electron micrograph from one of the areas of MBP pallor. Myelinated fibres are reduced and
astrocyte processes are increased. One axon (A1) has a myelin sheath of normal thickness; another (A2) has a thin sheath; a third (A3) has no
myelin sheath. Scale bar = 1 lm. Inset: Regular structure of major dense and intraperiod lines. Scale bar = 0.05 lm. (K and L) PMD and control
optic nerves, immunostained for MBP. Strong, generalized staining is present in both. Scale bars = 1 mm. (M) Area from PMD cerebellum immu-
nostained for MBP. The white matter is relatively well stained in the central part of the folium, tending to decrease in the branches. Two regions
of more reduced MBP staining are present (arrows). Scale bar = 1 mm. (N) Area from cerebellum from control for comparison. Scale bar = 1
mm. (O and P) Cerebellar white matter from folia stained by double immunofluorescence for MBP (green) and NF (red). In O, only a minority of
axons are lacking myelin whereas in P, an area of naked axons is present on the left with an island of myelin in the centre. Scale bars = 50 lm.
(Q) Higher magnification image. Few axons have an intact myelin sheath and the myelin is present as globules, suggesting demyelination. Scale bar
= 20 lm. (R) Cerebellar white matter from control for comparison with O and P. Scale bar = 50 lm. (S and T) Resin sections of the PMD cor-
pus callosum. There is a considerable loss of myelinated axons (asterisks) with replacement by astrocytic processes. Scale bars = 10 lm.
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columns and the periphery of the lateral columns (Fig. 3A
and B). Control spinal cord white matter was evenly stained
(Fig. 3C and D). Outside of the zones of pallor, the density
of nerve fibres appeared well preserved and the vast majority
of axons had myelin sheaths of appropriate thickness. The
difference between regions of strong and reduced myelin
protein immunostaining was exemplified in the posterior col-
umns contrasting the fasciculus gracilis, where there were
large numbers of demyelinated axons (Fig. 3E), with the per-
ipheral area of the fasciculus cuneatus, where the vast major-
ity of axons were well myelinated (Fig. 3F). Control material
is shown for comparison (Fig. 3G and H). Within the areas
of decreased immunostaining there was a marked loss of
fibres and a corresponding increase in astrocytic processes;
corpora amylacea were also common (Fig. 3I). Fibres with
thin myelin sheaths or naked axons were observed (Fig. 3J).
The myelin present was compacted and demonstrated major
dense and intraperiod lines (Fig. 3J, inset). Swollen axons
were seen infrequently (Fig. 3I). Myelin debris was infre-
quent and macrophages were not a feature in these regions
of spinal cord. Paraffin sections of optic nerve immunos-
tained strongly for PLP1/DM20 (not shown) and MBP
(Fig. 3K), similar to that of a control (Fig. 3L).
Immunostaining for MBP and PLP1/DM20 was present
throughout the medulla, cerebellum and cerebral cortex/sub-
cortical white matter; however, there was considerable vari-
ation within regions. For example, in the cerebellar white
matter the extent of staining tended to decrease into the folia
(Fig. 3M), which was not the case in the control, as expected
(Fig. 3N). Double immunostaining for MBP and SMI-31
(phosphorylated heavy chain neurofilament) suggested that
much of this patchy distribution was due to absence of mye-
lin from axons (Fig. 3O and P). Additionally, some of the
MBP-stained myelin was not associated with axons and
appeared to be present as globules, suggesting a degree of
demyelination (Fig. 3Q). In contrast, control cerebellum
MBP staining was largely homogenous (Fig. 3R). In PMD
corpus callosum there was clear evidence for axonal loss
with replacement by glial processes (Fig. 3S and T).
Developmental myelination
proceeds almost normally in a
mouse model of PLP1 duplication
mutation
To assess if direct cell transplantation into the CNS might
benefit patients with classical forms of PMD, we turned to a
Plp1-tg mouse model. The pathology and phenotype have
been overviewed previously (Readhead et al., 1994;
Anderson et al., 1999) but not characterized systematically.
Mice appeared almost indistinguishable from wild-type lit-
termates until around P90, after which they displayed a mild
ataxia and exhibited seizure activity. During the next month
of life, the generalized ataxia became progressively more
pronounced, a mild whole-body intention tremor developed,
and seizure activity increased in frequency. As described
previously, correlative histology and diffusion tensor imag-
ing at P120 revealed profound hypomyelination throughout
the brain, including grey and white matter (Ruest et al.,
2011), although the spinal cord remained well myelinated at
this age (data not shown). To define the evolution of the
pathology associated with these progressive neurological
signs we used electron microscopy to examine myelinated
axons in the mid corpus callosum between P40 and P120
(Fig. 4A). At P40, myelin appeared normal at the ultrastruc-
tural level and the percentage of axons with a myelin sheath
was similar to wild-type. However, although axon density
did not change compared to control (Supplementary Fig. 1),
the percentage of myelinated axons decreased progressively
over time until P120 when myelin sheaths were virtually ab-
sent (Fig. 4A and B). This progressive demyelination was
reflected, at the level of the light microscope, in a marked re-
duction in MBP immunostaining between P40 and P120
(Fig. 4C). Despite the loss of myelin, mature oligodendro-
cytes (identified with antibody CC1) were present in the cor-
pus callosum of Plp1-tg mice at all ages examined, including
P120 (Fig. 4D, arrows) although the number of CC1-posi-
tive cells appeared slightly diminished compared to wild-
type at P90 and P120 (Supplementary Fig. 1). These data
suggest demyelination is not, or only partly, due to oligo-
dendrocyte cell death. Correspondingly, caspase 3-positive
apoptotic cells were observed only occasionally in Plp1-tg
mouse corpus callosum (Fig. 4E).
These changes in myelination were associated with signifi-
cantly increased amounts of GFAP and of CD45-positive
microglia/macrophages from P60 onwards (data not shown),
and the appearance of sialoadhesin (CD169)-positive micro-
glia/macrophages and a small number of CD3-positive T
cells from P90 (Supplementary Fig. 2). Furthermore, focal
axon swellings were observed at P120, as visualized in Plp1-
tg::Thy1-YFP mice (Supplementary Fig. 2). At this age, Plp1-
tg mice had to be euthanized under the conditions of the UK
Home Office project licence.
In summary, normal-appearing developmental myelination
is followed by progressive demyelination, which is accompa-
nied by astrocytosis, neuroinflammation and axonal
changes. Notably, progressive demyelination has been
reported in other proteolipid-overexpressing models
(Mastronardi et al., 1993; Ma et al., 2006).
Plp1-tg oligodendrocyte precursor
cells are present throughout the
disease course in mice
These results demonstrate that Plp1-tg oligodendrocytes are
myelination-competent. Moreover, stained sections from
brains at ages P40, P60, P90 and P120, using antibodies
against NG2 (Fig. 5A) or PDGFRa (Fig. 5B), revealed a
density of OPCs similar to that in wild-type animals, and
possibly even increased compared to wild-type at P120
(Fig. 5G and H). The latter may be due to an increase in
proliferating PDGFRa-positive OPCs at P90 (Fig. 5B and I).
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Taken together, normal-appearing early myelination could
prevent a successful transplantation therapy with exogenous
OPCs, due to the competitive advantage of the endogenous
OPCs and oligodendrocytes.
Figure 5 Plp-tg mouse OPCs in adult brain mount a lim-
ited response to demyelination. (A and G) NG2 or (B inset,
and H) PDGFRa-positive OPCs were present in both wild-type and
Plp1-tg mouse corpus callosum at all ages examined, with NG2-
positive cells being at slightly but significantly higher density in the
P120 Plp1-tg animal compared to the age-matched control (G and
H). Wild-type is shown in orange, Plp1-tg in blue. Bars represent
mean ± SEM. (B and I) In both Plp1-tg and control animals, a small
number of BrdU-positive cells were present in the corpus callosum
at 1-h post-BrdU administration. (I) At P90, the number of
PDGFRa-positive cells double labelled with anti-BrdU was signifi-
cantly higher in the Plp1-tg animals compared to control (wild-type
in orange, Plp1-tg in blue). Bars represent mean ± SEM. (C–F and J)
The basic helix-loop-helix transcription factor OLIG1 translocates
to the nucleus during OPC differentiation and the subcellular local-
ization of the transcription factor can be used to assess the status
of the OPCs. In Plp1-tg corpus callosum, a small proportion of
NG2-positive cells had a nuclear localization of OLIG1 (C and J).
Most NG2-positive cells had a partially nuclear (D and J), cytoplas-
mic (E and J), or partially nuclear and partially cytoplasmic (F and J)
localization. Images were adjusted manually for brightness and con-
trast in Adobe Photoshop for ease of visualization.
Figure 4 Progressive demyelination in Plp1-tg mouse
brain. (A) Electron micrographs of the corpus callosum in wild-
type and Plp1-tg mice between P40 and P120. In Plp1-tg mice, at
P40 and to a lesser extent at P60, many axons are surrounded by
compact myelin, which appears ultra-structurally normal. The pro-
portion of myelinated axons is markedly diminished by P90 and vir-
tually all axons are devoid of myelin sheaths by P120. Astrocyte
processes (as) are particularly evident in Plp1-tg corpus callosum at
P90 and P120. (B) Graph demonstrating that the proportion of
myelinated axons in Plp1-tg mice is similar to wild-type at P40, but
diminishes over time. Bars represent mean ± standard error of the
mean (SEM). (C) Immunohistochemistry using antibody to MBP at
P120 demonstrates the extent of myelin loss across the corpus cal-
losum in Plp1-tg mice. (D) Antibody CC1-positive mature oligoden-
drocytes are still present in Plp1-tg corpus callosum at P120,
suggesting myelin loss is not, or only partially due to the death of
oligodendrocytes. (E) Accordingly, most sections of the corpus cal-
losum contained no cleaved caspase 3-positive cells. The positive
cell shown in the inset is one of the few cells observed. Scale bars =
2 lm in A; 400 lm in C; 10 lm in inset D.
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However, in light of the progressive loss of myelin
(Fig. 4), these data raise the possibility that unlike OPCs in
neonatal Plp1-tg mice (nOPC), mutant aOPCs may lose the
competence to synthesize myelin. To address this, we exam-
ined the intracellular localization of the basic helix-loop-
helix transcription factor, OLIG1, which translocates from
the oligodendroglial cytoplasm into the nucleus during
remyelination. Indeed, failure of this intracellular redistribu-
tion is associated with remyelination failure in multiple scler-
osis (Arnett et al., 2004). As expected, in Plp1-tg mice at age
P3, we found that the endogenous nOPCs exhibit an intra-
nuclear localization of OLIG1 (data not shown), whereas in
adult Plp1-tg mice, 53% of NG2-positive OPCs had a pure
nuclear localization at any age (Fig. 5C and J). In the adult
brains, similar to wild-type controls, OLIG1 localization in
NG2-positive OPCs was partially nuclear (Fig. 5D and J),
purely cytoplasmic (Fig. 5E and J); or partially nuclear and
partially cytoplasmic (Fig. 5F and J).
Collectively, these data are compatible with the absence of
effective myelin repair of the progressively demyelinating
adult Plp1-tg CNS, but do not allow us to distinguish
aOPC-intrinsic failure to remyelinate from an inhibitory
CNS environment for remyelination. These factors clearly af-
fect the likelihood of success of any cell transplantation
therapy.
Direct transplantation of neural
precursors into Plp1-tg brain results
in formation of compact myelin
To determine if the environment of the adult Plp1-tg mouse
brain allows (re)myelination, we transplanted a combination
of neurospheres expressing either GFP under the chicken b-
actin promoter or the lacZ reporter gene under the PLP1 pro-
moter into the brains of adult (P100) Plp1-tg mice.
Importantly, 14 days later, the transplanted cells appeared
fully integrated (Fig. 6A and B) and had formed compact
myelin around a small number of axons in the vicinity of the
transplant site (Fig. 6C and D), providing proof-of-principle
that the adult Plp1-tg brain remains myelination-competent.
However, a therapeutically more plausible approach would
be to transplant cells early in development. To test if the ex-
ogenous cells can survive and myelinate axons in the face of
competition from the endogenous, myelination-competent
Plp1-tg nOPCs, we next transplanted neurospheres to the
brains of P1 Plp1-tg mouse pups. At each of 7, 14, 35 and
120 days post-transplant (dpt), two mice were sacrificed and
1-mm thick slices of brain were stained with X-gal and eval-
uated. No transplanted cells were visible at 7 dpt. However,
at 14 dpt, a few isolated b-galactosidase positive cells with
myelin sheath-like morphologies were observed (Fig. 6E) and
at 35 (Fig. 6E and F) and particularly at 120 dpt (Fig. 6E and
G) large patches of X-gal staining were observed throughout
the brains including the corpus callosum, anterior commis-
sure, thalamus, hypothalamus, optic chiasm and hippocam-
pus. Electron micrographs of the corpus callosum of
transplant recipients demonstrated that compact myelin had
formed around numerous axons (Fig. 6H and I).
Unsurprisingly, the mice that received cell transplantation
at P100 did not have altered clinical signs. However, those
treated as neonates appeared normal at the point of euthan-
asia, including an absence of seizures in the two animals
euthanized at P120. Under the conditions of our UK Home
Office project licence we were unable to maintain the ani-
mals beyond that point.
Figure 6 Neural precursors form compact myelin sheaths
after transplantation into adult or neonatal Plp1-tg mice.
(A) Light microscopy image of beta galactosidase-positive cells in
the corpus callosum (delineated) of a Plp1-tg transplant recipient,
14 days post transplantation of PLP1-lacZ and b-actin GFP-express-
ing neurospheres into the brain at P100. (B) Corpus callosum of an-
other transplant recipient showing that transplanted GFP-positive
neurospheres form MBP-positive myelin. The red staining above the
upper line delineating the corpus callosum is from endogenous mye-
lin debris. (C and D) Electron micrographs showing that the trans-
planted cells generate oligodendrocytes that wrap axons with
normal-appearing myelin sheaths in which the inner tongue (black
arrow), periaxonal space (arrowhead) major dense lines (asterisks
in D inset) and intraperiod lines (dots in D inset) can be observed.
Scale bars = 400 lm in A; 2 lm in C; and 250 nm in D. (E) Light
microscopy image of beta galactosidase-positive cells in the corpus
callosum of Plp1-tg transplant recipients at 14, 35 and 120 dpt of
PLP1-lacZ expressing neurospheres into the brain at P1. (F and G)
Slices of transplant recipient brains (1-mm thick, presented rostral
to caudal) at 35 dpt (F) and 120 dpt (G), to illustrate how the trans-
planted cells distributed throughout the brain including the corpus
callosum (black arrow), anterior commissure (white arrow), thal-
amus (black arrowhead) and fimbria of the hippocampus (white
arrowhead). (H and I) Electron micrographs showing that the trans-
planted cells wrap axons with normal-appearing myelin sheaths in
which the periaxonal space, major dense lines and intraperiod lines
can be observed. Scale bars = 400 lm in A and E; 2 lm in C and
H; 250 nm in D and I; and 5 mm in F and G.
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Plp1-tg adult but not newborn
oligodendrocyte precursor cells fail
to differentiate normally in vitro
Given that Plp1-tg nOPCs form almost normal amounts of
myelin in vivo, we were surprised that cell transplantation
into neonatal Plp1-tg mice was so successful. Because we
had previously shown that oligodendrocyte survival and
myelination in the Plp1 mutants is influenced by ‘competing’
oligodendrocytes (Edgar et al., 2002) we next compared the
intrinsic differentiation potential of neonatal or adult Plp1-tg
OPCs to their wild-type counterparts, in cell culture. We co-
cultured Plp1-tg nOPCs (Fig. 7A) or Plp1-tg aOPCs
(Fig. 7B) with age-matched GFP-expressing wild-type cells
for up to 7 days then measured the extent of process exten-
sion. The mean total process length of anti-sulphatide (clone
O4) positive Plp1-tg nOPCs was similar to controls (Fig. 7A
and C), suggesting there is no competitive advantage for the
wild-type nOPCs with respect to their ability to extend mye-
lin-like sheets. However, the mean total process length of
Plp1-tg aOPCs was significantly reduced compared to con-
trols (Fig. 7B and D). These data suggest that intrinsic prop-
erties of Plp1-tg aOPCs account for or contribute to the
failure of effective remyelination in Plp1-tg mice, and could
provide a competitive advantage for exogenous wild-type
OPCs to wrap axons, following transplantation in neonates
or adults.
Cell transplantation reduces
neuroinflammation
Finally, we asked if transplantation of neural precursors and
restoration of wild-type myelin reduces neuroinflammation
(Supplementary Fig. 2). In resin sections of the corpus cal-
losum at P120, it was obvious at the level of the light micro-
scope that there were fewer ‘angular’ cells with dark nuclei
and cytoplasm in the transplant recipient compared with the
untreated control (Fig. 8A–C). By electron microscopy, these
dark, ‘angular’ cells contained dense chromatin, prominent
rough ER and dense lysosomes typical of phagocytic micro-
glia/macrophages (Fig. 8D–I). They were often observed
close to degenerate myelin profiles (Fig. 8D and E), oligo-
dendrocytes with swollen soma (Fig. 8F), astrocytic proc-
esses (Fig. 8G) or swollen axons (Fig. 8H and I). Their
‘angular’ appearance at the level of the light microscope was
likely due to the fact they extended long processes (Fig. 8G).
In contrast, in transplant recipients, it was more common to
observe oligodendrocytes; some with a small perinuclear
cytoplasm (Fig. 8J), presumably arising from the trans-
planted wild-type neural precursors; or with a large soma
(Fig. 8K), presumably of Plp1-tg origin. In contrast to the
untreated control, in which there were many areas filled
with astrocyte processes (Fig. 8G, yellow) or devoid of nor-
mal cellular contents (Fig. 8G, green), presumably represent-
ing axon loss, the majority of the space was occupied by
healthy-appearing myelinated and non-myelinated axons; al-
though occasional redundant myelin profiles were observed
(Fig. 8L). Activated microglia/macrophages were also occa-
sionally observed, such as those illustrated in Fig. 8M and
N, apparently engulfing a degenerate myelin profile
(Fig. 8M) or an adjacent cell (Fig. 8N). Having identified
these dense ‘angular’ cells as microglia/macrophages, we
quantified total cell profiles or microglia/macrophages in
resin sections. The total number of cells per area of interest
(5866 lm2) and the number of microglia/macrophages were
significantly decreased in the transplant recipient compared
Figure 7 Cell intrinsic factors prevent adult Plp1-tg OPCS
from differentiating normally. (A and B) GFP-positive wild-
type (WT) (black asterisks) and GFP-negative Plp1-tg OPCS (white
asterisks) were isolated from P5 forebrain (A) or adult corpus cal-
losum (B) and co-cultured for 7 days. (C and D) Graphs of total
process length per cell was measured from phase-contrast images
of anti-sulphatide-positive cells. There was no difference in mean
total process length of neonatal-derived Plp1-tg OPCs (C), which
form normal-appearing myelin in vivo, compared to wild-type cells
(Fig. 4). However, the mean total process length of Plp1-tg aOPCs
was significantly less than that of wild-type aOPCs (P5 0.0001; D).
Each data point represents one cell, from two or three independent
cultures, respectively. Each cell was considered independent for the
purpose of the statistical analysis. Bars represent mean ± SEM.
Note the different scales on the y-axes, demonstrating that even
wild-type aOPCs fail to expand processes to the same extent as
wild-type nOPCs. The images on the left were adjusted for bright-
ness and contrast using ‘auto’ in Adobe Photoshop for ease of
visualization.
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Figure 8 Neuroinflammation is reduced after transplantation. (A–C) Light microscopy of resin sections of corpus callosum of untreat-
ed (A) and transplant recipient (B and C) Plp1-tg mice at P120. Narrow black and white arrows indicate cell profiles, some of which (black
arrows) can be identified as microglia/macrophages, due to having a dark nucleus and dark cytoplasm. Cells with a dense nucleus but without a
dense cytoplasm (open white arrow in A) were not classified as microglia/macrophages. Occasionally, demyelinating axons (wide arrows in A
and B) were observed. Scale bar = 50 lm. (D) Microglia/macrophage (overlaid in turquoise) containing dense lysosomes (black arrows), promin-
ent mitochondria (yellow arrows) and rough endoplasmic reticulum (rER; white arrows) apparently engulfing degenerating myelin (asterisk).
Normal-appearing axons are also present (purple); one with a myelin sheath (lower left). Scale bar = 5 lm. (E) An oligodendrocyte (pink) in ap-
position to non-myelinated axons (purple). In the lower middle, an axon (purple) containing large mitochondria (yellow arrow), is surrounded by
degenerate myelin. Microglial/macrophage and astrocyte processes, turquoise and yellow respectively. Scale bar = 5 lm. (F) Oligodendrocyte
(pink) in close apposition to non-myelinated axons (purple), adjacent to a microglia/macrophage containing a dense lysosome and prominent rER
(black and white arrows, respectively). The yellow arrow points to one of two adjacent mitochondria. Scale bar = 5 lm. (G) A microglia/macro-
phage extending a long process with dense lysosomes (black arrows). The cell on the top right has prominent mitochondria (yellow arrow) and
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to the control (Fig. 8O). A similar reduction in microglia/
macrophages was also observed by immunofluorescence in
both transplant recipients terminated at P120.
Discussion
Here we describe two elderly brothers with duplication of
the PLP1 locus and provide proof-of-principle, in a corre-
sponding mouse model, for stem cell transplantation as a
therapeutic approach to PMD caused by duplication muta-
tions. In comparison to connatal forms of PMD, for which
neural stem cell transplantation has undergone safety trial
(Gupta et al., 2019), the patients described here had relative-
ly mild symptoms, which were nonetheless highly debilitat-
ing. Our patients’ symptom progression, radiological data
and end stage pathology are compatible with relatively ro-
bust developmental myelination; a supposition supported by
the fact that a cerebral biopsy from a 14-week-old relative
revealed ‘normal myelin sheaths’ (Watanabe et al., 1973). In
contrast, connatal PMD is characterized by a marked lack,
or complete absence, of myelin (van der Knaap and Valk,
1989; Duncan and Radcliff, 2016), raising the question
whether cell transplantation is a viable option for classical
forms of PMD, in which transplanted cells must compete
with endogenous cells for axon coverage and neuron-derived
trophic support (Barres et al., 1992; Barres and Raff, 1994,
1999).
To our knowledge, with only one exception (Marteyn
et al., 2016), all previous experimental studies addressing
cell transplantation as a therapy for PMD have been done in
animal models of connatal PMD where there is a marked
paucity of myelin from the outset (Duncan and Radcliff,
2016). Only the study of Marteyn et al. (2016) aimed at
PMD caused by PLP1 gene duplication, using our Plp1-tg
mice (but the less severe line #66; Readhead et al., 1994).
However, these investigators used human progenitors as
donor cells, which are well-known to be dominant, outgrow-
ing mouse OPC in the chimeric brain (Windrem et al.,
2002). Thus, the current study was able to address the critic-
al issue of how wild-type OPCs compete with Plp1-tg OPCs
within the same species; a highly therapy-relevant question
in humans. Indeed, we provide the first definitive demonstra-
tion using a transgenic model of PMD, where transplanted
neural stem cells of the same species successfully compete
against mutant OPCs and thus form myelin in the context of
relatively normal developmental myelination by ’mutant’
cells. This is likely relevant to other human leukodystrophies
in which oligodendrocytes exhibit developmental defects but
are nevertheless present as axon-ensheathing cells.
We previously demonstrated, using heterozygous female
Plp1 mutant mice that are mosaics harbouring two alleles of
the X-linked Plp1 gene, that despite being generated in equal
numbers, a hierarchy of survival favours those oligodendro-
cytes that express the least deleterious Plp1 allele. Thus,
oligodendrocyte survival and myelination in a competitive
environment is not determined solely by the nature of the
mutation, but also by competing cells (Edgar et al., 2002).
We speculated this was due to the ‘dominant’ cell being bet-
ter able to associate with axons and obtain essential survival
factors. In the current study, we found that despite Plp1-tg
nOPCs extending processes to a similar extent as their wild-
type counterparts in vitro, transplanted wild-type neural pre-
cursors eventually produced large amounts of compact mye-
lin in Plp1-tg transplant recipients. This suggests that the
exogenous wild-type cells (with a competitive advantage)
outcompete the endogenous aPlp1-tg OPCs to replace Plp1-
tg myelin as it degraded.
Incidentally, we also observed that the capacity of wild-
type aOPCs to extend processes in vitro is reduced in com-
parison to that of nOPCs (Fig. 7C and D). This, to our
knowledge, is the first report to show this phenotypic differ-
ence between nOPCs and aOPCs and has relevance for
understanding failure of remyelination, which is impaired
with increasing age (Neumann et al., 2019), in multiple
sclerosis.
The pathology observed in our patients is characterized by
regions containing large numbers of appropriately myelin-
ated axons interspersed with naked and thinly sheathed
axons and areas of axonal loss. While some of the naked
and thinly sheathed axons likely reflect persistent dysmyeli-
nation, others clearly represent demyelination. This conclu-
sion was also drawn in another recent report describing
findings in the corpus callosum in the same patients (Laukka
Figure 8 Continued
rER (white arrow). Astrocyte processes (yellow) and pale amorphous material (green), likely reflecting axon loss, were present. Scale bar = 5
lm. (H) Structure resembling a swollen, neurofilament-rich axon (asterisk) close to the process of a microglia/macrophage (turquoise). Most
axons appear normal but the pale areas of amorphous material (some shaded green) suggest axons have been lost. The pale nucleus probably
belongs to an astrocyte. (I) Microglia/macrophage (turquoise) next to an organelle-rich axon swelling (purple) and astrocyte process (yellow).
Scale bar = 2.5 lm. (J) A normal-appearing oligodendrocyte (pink) with a thin rim of cytoplasm is surrounded by myelinated axons. Scale bar =
2.5 lm. (K) Oligodendrocyte with an unusually large soma (as in E and F) containing mitochondria (yellow arrows) and swollen Golgi apparatus
(turquoise arrow), suggesting its origin from the Plp1-tg mouse. Scale bar = 2.5 lm. (L and M) Microglia/macrophages apparently engulfing a de-
generate myelin profile (L) and a cell resembling an oligodendrocyte (M). Scale bar = 5 lm. (N) Many normal-appearing myelinated axons along-
side two redundant myelin profiles (black arrows). The cell in the top right has prominent rER, and a chromatin-rich nucleus. Scale bar = 5 lm.
(O) Graph indicating total numbers of cell profiles (white bars) and numbers of ‘activated’ microglia/macrophages (grey bars) per area of interest
(AOI) in untreated and transplant recipient P120 Plp1-tg mice. Bars represent mean ± SD. The transplant recipient harboured significantly fewer
total cells (P5 0.0001) including significantly fewer microglia/macrophages (P5 0.0001) than the untreated control; taking each area of interest
as an independent sample.
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et al., 2016). In fact, our patients exhibited a phenotype
resembling that in the #72 Plp1-tg line described in this
study and in other lines with intermediate or low Plp1/PLP1
transgene dosage, that undergo demyelination and axonal
degeneration in adulthood (Mastronardi et al., 1993; Inoue
et al., 1996; Anderson et al., 1998, 1999).
In the patients, axonal degeneration was observed in all
regions examined but particularly in the periphery of the lat-
eral and in the posterior columns of the spinal cord. In con-
trast, in patients lacking PLP1 due to a null mutation of the
gene, axon degeneration primarily affects the corticospinal
tracts and fasciculus gracilis, consistent with length-depend-
ent degeneration (Garbern et al., 2002). The current findings
contribute to evidence that axonal degeneration is a major
feature of some phenotypes of PMD (Garbern et al., 2002;
Laukka et al., 2016); however, the mechanisms remain ob-
scure. Experimental studies in line #66 Plp1-overexpressing
mouse model of PLP1 duplication, demonstrate that CD8-
positive T cells contribute to the pathogenesis of myelin and
axon injury (Ip et al., 2006) and Plp1 ‘overexpression’ in
mice is clearly associated with a marked neuroinflammation
involving microglia/macrophages, astrocytes and limited T-
cell infiltration (Ip et al., 2006, 2007; Edgar et al., 2010).
However, the earliest axon changes in mouse models and
in the patients described here likely represent a secondary re-
sponse to the injured ‘mutant’ myelin. Whilst the level of
CNP in the biopsy specimen from the 14-week-old relative
of our patients was reported as normal (Watanabe et al.,
1973), we found reduced levels of CNP and also of MAG in
our patients. In contrast, MBP was present in myelin at lev-
els similar to controls. While an increase in PLP1/DM20
was anticipated, it is not clear why CNP and MAG were
reduced although a reduction in both has also been noted in
hemi- and homozygous line #66 Plp1-tg mice (Karim et al.,
2007). CNP acts as an intracellular strut to prevent compac-
tion of the cytoplasm-filled space at the periphery of the
oligodendrocyte process (Snaidero et al., 2017) and reduced
levels of CNP could potentially interfere with trafficking be-
tween the glial cell body and the glia-axonal junction, result-
ing in impaired metabolic support of axons (Saab et al.,
2013; Stassart et al., 2018) and secondary axon degener-
ation (Lappe-Siefke et al., 2003; Edgar et al., 2009).
Reduction in levels of MAG, which binds to receptors on
the axolemma (Yang et al., 1996; Yamashita et al., 2002;
Pan et al., 2005; Schnaar and Lopez, 2009), could also po-
tentially interfere with the normal glial-axonal interaction. In
rodents with spontaneous mutations in myelin genes, loss of
MAG from the oligodendrocyte inner tongue is associated
with demyelination (Bo¨ et al., 1995; O’Connor et al., 2000;
Song et al., 2001) and degeneration of the myelin inner
tongue has been reported in aged hemizygous #66 Plp1-tg
mice (Fig. 8; Anderson et al., 1998). Cell transplantation
appeared to reduce axon loss in this study (compare Fig. 8I
and N), but whether this was due directly to restoration of
normal myelin and of myelin proteins, to reducing neuroin-
flammation including T-cell infiltration, or a combination of
both, remains undetermined.
Two previous reports of patients with confirmed PLP1
duplication (Cremers et al., 1987; Harding et al., 1995)
emphasize the myelin deficit. In contrast to the brothers
described here, both patients were young at the time of
death. The patient described by Harding et al. (1995) like-
ly has a triplication of the PLP1 gene, and the patient
described by Cremers et al. (1987) had an interstitial trans-
location of the X chromosome, which may account for the
more complex syndrome including dysmorphic features
not generally observed in patients with classical PMD. A
similarly severe phenotype in mice with high Plp1/PLP1
transgene dosage (Kagawa et al., 1994; Readhead et al.,
1994; Anderson et al., 1999) is associated with sequestra-
tion of PLP1 and cholesterol in endosomes/lysosomes
(Simons et al., 2002) that, paradoxically, can be rescued
by cholesterol supplementation in a mouse model (Saher
et al., 2012), but not in PMD patients, likely due to differ-
ences in blood–brain barrier permeability between the two
species in the context of this disease (Stumpf et al., 2019).
However, a ketogenic diet, which does not require a per-
meable blood–brain barrier for entry of ketones into the
CNS, improves axon function and restores axonal mito-
chondrial size in the same mouse model (Stumpf et al.,
2019). This raises the possibility that early dietary inter-
vention combined with transplantation of neural precur-
sors could markedly improve disease prognosis through
restoration of myelin and dietary-mediated neuroprotec-
tion, currently a critical unmet clinical need in demyelinat-
ing disease (Franklin and Kotter, 2008; Irvine and
Blakemore, 2008; Wilkins and Scolding, 2008).
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